Evaluation of the therapeutic effect of budesonide combined with interferon nebulization inhalation in the treatment of viral pneumonia in children
布地奈德联合干扰素雾化吸入在治疗儿童病毒性肺炎中的疗效评价

摘要

目的 分析布地奈德联合干扰素雾化吸入在治疗儿童病毒性肺炎中的疗效评价。方法 选择2022年1月-2022年6月在我院儿科治疗的病毒性肺炎患儿50例，在此期间采取常规治疗并作为对照组；选择2022年7月-2023年1月在我院儿科治疗的病毒性肺炎患儿50例，在此期间采取布地奈德联合干扰素雾化吸入治疗并作为观察组。结果 观察组的患儿的肺部功能恢复时间和治疗时间均小于对照组；观察组的患儿家属满意度高于对照组；观察组患儿各项症状缓解时间均小于对照组；差异均有统计学意义（P＜0.05）。结论 在对病毒性肺炎患儿实施布地奈德联合干扰素雾化吸入治疗取得明显效果。

Abstract

Objective To analyze the efficacy evaluation of budesonide combined with interferon nebulization inhalation in the treatment of viral pneumonia in children.
Methods Select 50 children with viral pneumonia treated in our pediatric department from January 2022 to June 2022, during which they will receive routine treatment and serve as the control group; Select 50 children with viral pneumonia treated in our pediatric department from July 2022 to January 2023. During this period, they will be treated with budesonide combined with interferon nebulization inhalation as the observation group.
Results The recovery time and treatment time of lung function in the observation group were both shorter than those in the control group; The satisfaction of the families of the children in the observation group was higher than that in the control group; The relief time of various symptoms in the observation group was shorter than that in the control group; The differences were statistically significant (P<0.05).
Conclusion   The implementation of budesonide combined with interferon nebulization inhalation therapy in children with viral pneumonia has achieved significant results.